Quick Answer
TScan Therapeutics, Inc. reported Total Revenue of $10.33 million for the year ending 2025.
- TScan Therapeutics, Inc. showed an increase of +266.7% in Total Revenue from 2024 to 2025.
- This data is from TScan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $290.0 thousand | Q1 2021: $2.03 million | Q2 2021: $2.85 million | Q3 2021: $2.41 million | Q1 2022: $3.02 million | Q2 2022: $4.06 million | Q3 2022: $3.36 million | Q1 2023: $6.80 million | Q2 2023: $3.15 million | Q3 2023: $3.89 million | Q1 2024: $566.0 thousand | Q2 2024: $536.0 thousand | Q3 2024: $1.05 million | Q1 2025: $2.17 million | Q2 2025: $3.08 million | Q3 2025: $2.51 million.
- Over the full 6 years of available data (2020 to 2025), TScan Therapeutics, Inc.'s Total Revenue has grown by 851.6%.
- Historical annual values: Fiscal year 2025: $10.33 million | Fiscal year 2024: $2.82 million | Fiscal year 2023: $21.05 million | Fiscal year 2022: $13.54 million | Fiscal year 2021: $10.14 million | Fiscal year 2020: $1.09 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: